OpenAI says its forthcoming Astra model is the first it has designated at the Critical cybersecurity capability level under its Preparedness Framework, with advanced cyber access planned for limited testers first.
The European Medicines Agency launched a voluntary data-submission pilot for New Approach Methodologies, giving developers a non-binding route to discuss organoid, microphysiological, computational and mixed-method data with regulators.
AWS announced general availability of EC2 R9g and R9gd instances powered by Graviton5, targeting memory-intensive databases, caches, analytics and container workloads across four initial regions.
AWS announced two same-day AgentCore Memory updates: fine-grained access control through AgentCore Gateway and flexible namespace variables for long-term memory organization in multi-tenant agent applications.
The FDA approved Takeda's Mimrylo for adults with polycythemia vera, citing a phase 3 trial in which 76.9% of treated participants avoided phlebotomy during weeks 20 to 32 compared with 32.9% on placebo.
OpenAI says it has notified SpaceX that it plans to end the contract supplying OpenAI models to Cursor after Cursor became part of SpaceX, with a proposed shutoff date in November and no future models planned for the coding platform.
Newsletter
Independent coverage of artificial intelligence, enterprise technology and medicine — written for readers who want to understand not only what happened, but why it matters.
Newsletter coming soon.
We are preparing the newsletter. Check back here for sign-up details when it launches.
